Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
References
Additional references
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non‐small‐cell lung cancer: results of a 1‐year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387 (10026):1415‐26. [DOI: 10.1016/S0140‐6736(16)00004‐0]
US Department of Health and Human Services. Common terminology criteria of adverse events (CTCAE). Version 4.03. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 16 November 2016).
Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, et al. Meta‐analysis of single‐agent chemotherapy compared with combination chemotherapy as second‐line treatment of advanced non‐small‐cell lung cancer. Journal of Clinical Oncology 2009;27(11):1836‐43.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136(5):E359‐86.
Gao G, Ren S, Li A, He Y, Chen X, Li W, et al. A meta‐analysis of comparing EGFR‐TKI with chemotherapy as the second‐line treatment of NSCLC patients with wild‐type EGFR. Journal of Clinical Oncology 2013;31(Suppl 1):15.
Guyatt GH, Oxman AD, Vist G, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE Working Group. Rating quality of evidence and strength of recommendations ‐ GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal 2008;336:924‐6.
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan‐Meier survival curves. BMC Medical Research Methodology 2012;12:9.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from handbook.cochrane.org.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 2011;343:d5928.
Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta‐analyses: a large survey. Canadian Medical Association Journal 2007;176(8):1091‐6.
Laurie SA, Goss GD. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild‐type non–small‐cell lung cancer. Journal of Clinical Oncology 2013;31(8):1061‐9.
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non‐small cell lung cancer harboring wild‐type epidermal growth factor receptor: a meta‐analysis. Journal of the American Medical Association 2014;311(14):1430‐7.
Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY. Meta‐analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second‐line treatment in pretreated advanced non‐small cell lung cancer. PLOS One 2014;9(7):e102777.
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology 2013;8(7):823‐59.
Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Brahmer JR, et al. Systemic therapy for stage IV non‐small‐cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 2015;33(30):3488‐515.
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non‐small‐cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). American Journal of Cancer Research 2015;5(9):2892‐911.
Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M, et al. ESMO Guidelines Committee. Metastatic non‐small‐cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2016;27(Supplement 5):v1–27.
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second‐line chemotherapy in previously treated advanced non‐small‐cell lung cancer: a systematic review and meta‐analysis. Asian Pacific Journal of Cancer Prevention 2012;13(10):5177‐82.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27(6):746‐63.
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla K, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small‐cell lung cancer previously treated with platinum‐based chemotherapy. Journal of Clinical Oncology 2000;18(10):2095‐2103.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000;92(3):205‐16.
Vale CL, Burdett S, Fisher DJ, Navani N, Parmar MK, Copas AJ, et al. Should tyrosine kinase inhibitors be considered for advanced non‐small‐cell lung cancer patients with wild type EGFR? Two systematic reviews and meta‐analyses of randomized trials. Clinical Lung Cancer 2015;16(3):173‐82.
Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second‐line treatment in advanced non‐small‐cell lung cancer with wild‐type EGFR: a meta‐analysis of randomized controlled clinical trials. Lung Cancer 2014;85(1):66‐73.
